ArticleMedComm2026

All-Oral PI3Kδ and HDAC Inhibition with Parsaclisib Plus Chidamide and Step-Down Maintenance in Relapsed or Refractory Peripheral T-Cell Lymphoma: A Phase Ib Trial.

Xufeng Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.